Pfizer (NYSE: PFE) has been a nightmare for many investors in recent years. At one point earlier this year, the big pharma stock was nearly 60% below its peak set in late 2021. However, the narrative ...

Anyone who has followed Pfizer lately knows it offers a high forward dividend yield of over 5.3%. The drugmaker has increased its dividend for 15 consecutive years. Income investors should love that ...

Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks to its work in this area, once the pandemic started receding, sales from ...